Articles
When breast cancer recurs or is diagnosed at an advanced stage, treatment is complicated by the diverse nature of the disease, with several molecular subgroups with distinct tumor biology responding differently to different therapies.
Read More ›
For patients with advanced breast cancer, prognosis remains especially suboptimal, primarily because of acquired pharmacologic resistance. Fortunately, several new drugs and drug combinations have recently become available.
Read More ›
Breast cancer is not simply one disease, and the use of more effective therapies that target different tumor markers, such as the cyclin-dependent kinase (CDK)4/6 pathway in estrogen receptor–positive breast cancer, may actually reduce the total cost of care for patients/members and payers.
Read More ›
An open conversation with a patient at this transition point of an MBC diagnosis should stress that, although the disease may be incurable, care can focus on control and hope as long as possible, with a balance for quality of life.
Read More ›
Chicago, IL—Alectinib (Alecensa), a next-generation anaplastic lymphoma kinase (ALK) inhibitor, was called a new standard of care for patients with ALK mutation–positive non–small-cell lung cancer (NSCLC), based on results of the phase 3 ALEX clinical trial, which were presented at the 2017 ASCO annual meeting.
Read More ›
Adding abiraterone to standard initial treatment that includes androgen-deprivation therapy (ADT) increased survival and reduced mortality risk by 37% over 3 years versus standard of care in the STAMPEDE study of men with locally advanced or metastatic prostate cancer.
Read More ›